So I've been thinking over the weekend what Questcor's plans are for the future. They have repeatedly said that they are not looking for another drug and just want to continue to focus on Acthar and its 19 indications.I personally think Questcor management as astute. They have made all the right decisions to take Acthar to near blockbuster status and have made a ton of money for shareholders along the way.So they are kind of at a cross-roads here. Acthar has taken the company beyond, and now, management has tons of cash to draw upon. If you were management, what would you do?Some ideas:- Take Acthar international- Partner with a major drug company- Develop or buy another drug/company (although management has said they have no plans for this)I'm fairly excited to see what management will do. The stock is down since the JP Morgan Healthcare conference probably because the company did not offer any hints or provide additional information on scripts other than they are greater than last quarter...which is good news, but analysts were hoping for more information.Carl
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat